Business
Covalon Announces Major Milestone: Achieves FDA Approval for IV Clear(tm) - a Breakthrough Antimicrobial Silicone Adhesive Film Dressing for Securing Vascular Access Medical Devices
MISSISSAUGA, ON, May 15, 2012 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon"...
About this update from Covalon Technologies Ltd.
[{"type":"text","content":"\n\n\n\n\n\nMISSISSAUGA, ON, May 15, 2012 /CNW/ - Covalon Technologies Ltd. (the\n \"Company\" or \"Covalon\") (TSXV: COV), an advanced medical technologies\n company, today announced United States Food and Drug Administration\n (\"FDA\") approval of IV ClearTM, a breakthrough antimicrobial silicone adhesive film dressing designed\n for securing vascular intravenous access devices.\n\n\nCovalon's IV Clear antimicrobial film dressings have a number of unique\n and highly desirable characteristics:\n\n\nIV Clear is the only vascular access securement dressing approved by the\n FDA that combines the comfort of skin-friendly silicone adhesive\n technology with the advanced antimicrobial protection of two gold-standard antimicrobial agents - chlorhexidine and silver.\n\n\nIV Clear has uniquely bonded the two antimicrobials into the actual\n adhesive of the soft and non-sensitizing silicone that allows the clear\n film dressing to comfortably secure vascular access devices to the skin\n while providing antimicrobial protection for up to 7 days.\n\n\nIV Clear is breathable unlike most other silicone dressings.\n\n\nPatients are able to bathe while wearing the waterproof silicone IV\n Clear dressing.\n\n\nAll the current leading suppliers of vascular access securement\n dressings use acrylic adhesives instead of the much superior and more\n skin-comfortable silicone.\n\n\nStudies have shown that IV Clear is up to ten times less painful on\n removal than leading film dressings that use acrylic adhesives.\n\n\n\"IV Clear is truly a new innovation in the fight against Catheter\n Related Blood Stream Infections (CRBSI), for which the Center for\n Disease Control (CDC) calls one of the most deadly and costly threats\n to patient safety,\" said Brian Pedlar, Covalon's Chief Executive\n Officer. \"Having an antimicrobial silicone adhesive is a clear\n advantage over the older generation of patches, pads or acrylic\n adhesive technologies currently available in the market.  With over 350\n million IV catheter stabilization devices used in the United States\n alone and the adoption of antimicrobial securement devices experiencing\n double-digit growth, we fully expect IV Clear to be a strong competitor\n in the market.\"\n\n\nIV Clear is intended to cover and protect insertion sites and to secure\n the various intravenous devices to a patie...